Sacred Mushroom Psilocybin (Psilocybe cubensis): Benefits, Dosage, Safety & Evidence

Frequently asked questions

How does psilocybin work in the brain?

Psilocybin is a prodrug that the body rapidly converts to psilocin, which acts primarily as an agonist at 5-HT2A serotonin receptors in the brain. This binding increases neural connectivity and alters default mode network activity, producing characteristic psychedelic effects. Research suggests this mechanism promotes neuroplasticity and may help disrupt rigid thought patterns associated with depression and PTSD. Evidence level: C (preliminary clinical evidence).

Can you take psilocybin mushrooms with antidepressants?

SSRIs and other antidepressants can significantly reduce psilocybin's effects due to serotonin receptor downregulation. Conversely, MAOIs may dangerously potentiate effects and increase serotonin syndrome risk. Case reports document seizure risk when combining psilocybin with lithium. Individuals taking psychiatric medications should only use psilocybin in clinical settings with proper medical oversight and medication tapering protocols. Evidence level: C (case reports and pharmacological evidence).

What is the therapeutic dose of psilocybin mushrooms?

Clinical trials for depression typically administer 10-25mg synthetic psilocybin, roughly equivalent to 1-3 grams of dried Psilocybe cubensis, though potency varies significantly between specimens. Traditional Mazatec healing ceremonies historically used similar amounts. Therapeutic outcomes depend heavily on preparation, setting, and integration support. Dosage should only be determined within clinical trial protocols or legal therapeutic frameworks. Evidence level: C (preliminary clinical evidence).

Is psilocybin safe during pregnancy and breastfeeding?

Psilocybin is unsafe during pregnancy and breastfeeding. No adequate human studies exist, but animal research suggests potential fetal risks. The cardiovascular effects, including increased heart rate and blood pressure, pose additional pregnancy concerns. Psilocybin may also affect uterine smooth muscle. Women who are pregnant, planning pregnancy, or breastfeeding should avoid psilocybin entirely. Evidence level: D (expert opinion based on pharmacological properties).

Who should not take psilocybin mushrooms?

Psilocybin is contraindicated for individuals with personal or family history of psychosis, schizophrenia, or bipolar disorder due to increased risk of triggering psychotic episodes. Those with severe cardiovascular disease face risks from elevated heart rate and blood pressure. The substance is also contraindicated during pregnancy. Clinical trial screening protocols systematically exclude these populations for safety reasons. Evidence level: C (clinical exclusion criteria and case reports).

PubMed-compiled information sheet

This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.

Compiled from 30 PubMed articles · model: gemma4:31b

Summary

Psilocybe cubensis is a psychoactive mushroom containing psilocybin and psilocin, currently being investigated for the treatment of major depressive disorder and anxiety [PMID:39257234, PMID:40258947].

Background

Psilocybe cubensis, often called 'magic mushroom,' is a species of psilocybin mushroom [PMID:38236234]. It was initially described from Cuba in 1906 and is now cultivated worldwide for medicinal and recreational use [PMID:41818815].

Traditional uses

South American Aztec Indians referred to these mushrooms as teonanacatl ('god's flesh') and used them in healing and religious rituals [PMID:32398764]. Pre-Columbian Mesoamerican cultures used hallucinogenic mushrooms to induce altered states of consciousness during religious ceremonies and healing rituals [PMID:21893367].

Active compounds

The principal active compounds are the indole alkaloids psilocybin (4-phosphoryloxy-N,N-dimethyltryptamine) and its active metabolite psilocin [PMID:32398764, PMID:38236234]. Other related tryptamines found in P. cubensis include baeocystin, norbaeocystin, and aeruginascin [PMID:33119971].

Mechanism of action

Psilocybin acts as a prodrug that is dephosphorylated to psilocin by alkaline phosphatase [PMID:39257234]. Psilocin is believed to exert its effects by binding to the serotonin 5-HT2A receptor, although evidence also suggests a mechanism involving membrane-mediated receptor desensitization of neurotransmitter receptors [PMID:35561790].

Clinical evidence

Evidence CMajor Depressive Disorder

Psilocybin has drawn attention as a breakthrough therapy for treating major depressive disorder [PMID:39257234] and has shown potential medical value in psilocybin-assisted psychotherapy [PMID:32398764].

Evidence DPTSD-like behavior (Rat Model)

Psilocybe cubensis extract potently prevented fear memory recall and freezing behavior in short-term (but not long-term) rat models of PTSD [PMID:38236234].

Evidence DAnxiety and Depression (Mice Models)

P. cubensis mushroom extracts demonstrated antidepressant- and anxiolytic-like activities in experimental mouse models [PMID:37977425, PMID:42076014].

Safety & adverse effects

A review concluded that the physical and psychological dependence potential of magic mushrooms is low, acute toxicity is moderate, and chronic toxicity is low [PMID:21256914]. In mice, the acute toxicity (LD50) of P. cubensis was determined to be 2000 mg/kg via oral and intraperitoneal routes [PMID:37977425].

Evidence summary

Evidence consists primarily of preclinical animal models (D), historical reviews (C), and systematic reviews of pharmacokinetics (A). Clinical human evidence is mentioned in reviews as being in the context of FDA-approved studies and breakthrough therapy designations, but specific RCT results for P. cubensis whole mushroom are limited.

PubMed sources

1.PMID: 32398764 (2020) — Psilocybin: from ancient magic to modern medicine. · The Journal of antibiotics
2.PMID: 35918311 (2022) — Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study. · Translational psychiatry
3.PMID: 39257234 (2025) — Pharmacokinetics of Psilocybin, a Tryptamine Alkaloid in Magic Mushroom (Psilocybe cubensis): A Systematic Review. · Journal of psychoactive drugs
4.PMID: 40258947 (2025) — Development of a PBPK model of psilocybin/psilocin from Psilocybe cubensis (magic mushroom) in mice, rats, and humans. · Scientific reports
5.PMID: 37518950 (2023) — Biosynthesis of kratom opioids. · The New phytologist

Sacred Mushroom Psilocybin

Sources & Citations

Calculate a safe dose of Sacred Mushroom Psilocybin

Xiao Yao San Patent

Aralia Russian

Centella Indian

Frequently asked questions

Summary

Background

Traditional uses

Active compounds

Mechanism of action

Clinical evidence

Safety & adverse effects

Evidence summary

PubMed sources

Government sources

Sacred Mushroom Psilocybin

Sources & Citations

Calculate a safe dose of Sacred Mushroom Psilocybin

Related Herbs

Xiao Yao San Patent

Aralia Russian

Centella Indian

Frequently asked questions

Summary

Background

Traditional uses

Active compounds

Mechanism of action

Clinical evidence

Safety & adverse effects

Evidence summary

PubMed sources

Government sources